Dr. Haipeng Yu 于海鹏
Chief Physician
Department of Interventional Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive interventional therapy for benign and malignant solid tumors, including inoperable liver cancer, liver metastases, lung cancer, melanoma, pancreatic cancer, renal cell carcinoma, prostate cancer, soft tissue sarcoma, hemangiomas, and uterine fibroids. Techniques include argon-helium cryoablation, microwave ablation, radioactive seeds, molecular targeted drugs, and immunotherapy.
Dr. Yu is Deputy Director and Chief Physician of the Department of Interventional Therapy at Tianjin Medical University Cancer Institute & Hospital. Holding a medical doctorate, Dr. Yu serves as a master’s supervisor and attending physician. Recognized as New Century Talent at the hospital, Dr. Yu teaches English to international students and serves as a certified trainer for national minimally invasive interventional oncology programs.
Professional roles
- Vice Chair, Interventional Oncology Professional Committee, China Anti-Cancer Association (2021)
- Vice Chair, Interventional Diagnosis and Treatment Branch, International Exchange and Promotion Association of Healthcare (2021)
- Standing Committee Member, Tumor Ablation Therapy Expert Committee, Chinese Society of Clinical Oncology (CSCO) (2024)
- Standing Committee Member, Tumor Ultrasound Therapy Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Yu Haipeng). Papers usually list the name as Haipeng Yu or Yu H.
Selected publications
43 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Surg, 2026 (senior author): Safety and efficacy of a novel four-hook needle versus hook wire for CT-guided preoperative localization of pulmonary nodules: a propensity score-matched analysis. PubMed 42909064
- Sci Rep, 2026 (senior author): A machine learning model for predicting pneumothorax risk after computed tomography-guided percutaneous transthoracic needle biopsy: A two-hospital retrospective study. PubMed 42323415
- Discov Oncol, 2025 (senior author): A bibliometric analysis of atezolizumab in hepatocellular carcinoma. PubMed 41051650
- Front Immunol, 2025 (senior author): Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging. PubMed 40529364
- Acad Radiol, 2024 (senior author): Efficacy and Safety of CT-guided Percutaneous Cryoablation for Hepatocellular Carcinoma at High-risk Sites. PubMed 38749870
- Front Oncol, 2022 (senior author): Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: A bibliometric and knowledge-map analysis. PubMed 36686799
- Front Oncol, 2022 (first author): Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer. PubMed 36072793
- J Cancer Res Ther, 2020 (senior author): Should the Oddis sphincter be retained? A clinical analysis of biliary metal stent implantation in patients with malignant obstructive jaundice. PubMed 33004757
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion